Zi-jun Xu

jiangsu university

H指数:19

被引数:1,519

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular international prognostic index prognostic model in diffuse large B-cell lymphoma

弥漫大B细胞淋巴瘤的分子国际预后指数预后模型

Discover Oncology

IF2.9

2026-03-130

OAAI

Comprehensive characterization of VSIR reveals dual epigenetic regulation and immune landscape across hematological malignancies

VSIR的全面表征揭示了血液系统恶性肿瘤中表观遗传调节的二元性及免疫景观

Scientific Reports

IF3.9

2026-03-020

A rare cytogenetically cryptic MECOM rearrangement in a patient with myelodysplastic neoplasm and SF3B1 mutation identified by RNA sequencing: a case report

Frontiers in Oncology

IF3.3

2026-01-190

OAAI

Identification and validation of HOXB3 hypomethylation as a novel prognostically epigenetic biomarker in acute myeloid leukemia

HOXB3低甲基化作为急性髓系白血病中一种新型的预后表观遗传生物标志物的鉴定与验证

Frontiers in Immunology

IF5.9

2026-01-130

OAAI

Global profiling of protein lysine Malonylation during goat intramuscular Preadipocyte differentiation

山羊肌内前体脂肪细胞分化过程中蛋白质赖氨酸丙二酰化修饰的全球性分析

proteomics

IF2.8

2025-08-120

PRE

Overexpression and oncogenic role of RIPK3 in acute myeloid leukemia associated with specific subtypes and treatment outcome

BMC CANCER

IF3.4

2025-02-130

OAAI

Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia

鉴定HOXA9甲基化作为预测急性髓系白血病预后和指导治疗选择的表观遗传生物标志物

BMC CANCER

IF3.4

2025-02-070

OAAI

Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity

FRONTIERS IN IMMUNOLOGY

IF5.9

2025-02-050

OAAI

Identification of biomarkers for tumor regression grade in esophageal squamous cell carcinoma patients after neoadjuvant chemoradiotherapy

FRONTIERS IN ONCOLOGY

IF3.3

2025-01-170

OAAI

Lorlatinib in the treatment of a rare pulmonary mucoepidermoid carcinoma with EML4-ALK fusion: a case report and literature review

氯拉替尼治疗伴EML4-ALK融合的罕见肺黏液表皮样癌1例并文献复习

FRONTIERS IN ONCOLOGY

IF3.3

2024-08-290

PRE

Identification and validation of necroptosis-related gene signatures to predict clinical outcomes and therapeutic responses in acute myeloid leukemia

坏死性凋亡相关基因特征的鉴定和验证，以预测急性髓系白血病的临床结果和治疗反应

AGING-US

IF3.9

2023-11-210

OAAI

Comprehensive characterization of TGFB1 across hematological malignancies

SCIENTIFIC REPORTS

IF3.9

2023-11-046

OAAI

Litter decomposition and nutrient release are faster under secondary forests than under Chinese fir plantations with forest development

SCIENTIFIC REPORTS

IF3.9

2023-10-0516

OAAI

Abnormal regulation of miR-29b-ID1 signaling is involved in the process of decitabine resistance in leukemia cells

CELL CYCLE

IF3.4

2023-04-096

SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia

CLINICAL EPIGENETICS

IF4.4

2022-12-022

OAAI

Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation

BMC CANCER

IF3.4

2022-11-292

OAAI

Intrachromosomal Looping and Histone K27 Methylation Coordinately Regulates the lncRNA H19-Fetal Mitogen IGF2 Imprinting Cluster in the Decidual Microenvironment of Early Pregnancy

早孕蜕膜微环境中染色体内成环与组蛋白K27甲基化协同调控lncRNA H19-Fetal丝裂原IGF2印迹簇

CELLS

IF5.2

2022-10-056

OAAI

Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia

MOLECULAR THERAPY ONCOLYTICS

IF5.3

2022-09-016

OAAI

SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm

LEUKEMIA

IF13.4

2022-07-298

PRE

DNA methylation-mediated differential expression of DLX4 isoforms has opposing roles in leukemogenesis

CELLULAR & MOLECULAR BIOLOGY LETTERS

IF10.2

2022-07-263

OAAI

Zi-jun Xu

个人简介

教育背景

工作经历

荣誉奖项

研究方向